Drugs / BCMA/CD19 dual-target CAR-T cell immunotherapy
BCMA/CD19 dual-target CAR-T cell immunotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04412889 | Jun 2020 → Dec 2022 | plasma cell myeloma | Hebei Yanda Ludaopei Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA/CD19 dual-target CAR-T cell immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04412889 ↗ |
| Modality | Cell therapy | “CAR-T cell immunotherapy” NCT04412889 ↗ |